Do You Have These Biotech Stocks In Your Portfolio?

(RTTNews) - The biotech sector is highly volatile and unpredictable as it is driven by regulatory and clinical trial catalysts, which can make or break the stock prices.

Listed below are some of our stock picks that have rallied decently and with the potential for big moves depending upon the outcomes of the clinical trial/regulatory catalysts. The stocks were featured in our In the Spotlight column.

1. Strongbridge Biopharma plc (SBBP)

Strongbridge is a rare disease biopharmaceutical company with commercial and late-stage product portfolio.

SBBP was trading around $7.55 when it featured in our In the Spotlight column on January 5, 2018. It touched a 52-week high of $9.25 on April 2, 2018, reflecting a gain of 22.5% from the published price. The stock has given back all its gains and currently trades around $7.00.

What next?

The Company expects to report top-line results from a phase III trial of investigational drug RECORLEV in endogenous Cushing's syndrome, dubbed SONICS, in mid-2018.

The commercial launch of MACRILEN, the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency, a rare endocrine disorder, is on track for July 2018.

2. Immuron Limited (IMRN)

Immuron, an Australian biopharmaceutical company, is focused on developing oral drugs for various immune mediated and inflammatory disorders like non-alcoholic steatohepatitis (NASH) diabetes, colitis, arthritis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders.

IMRN was trading around $7.40 when it featured in our In the Spotlight column on January 12, 2018. It touched a 52-week high of $16.70 on March 8, 2018, reflecting a gain of 125.6% from the published price. The stock has given back all its gains and currently trades around $8.72.

The Company reported positive results from its phase II study of IMM-124E in NASH on March 8, 2018, sending the stock up 97% that day.

What next?

A phase II trial of IMM-124E in pediatric nonalcoholic fatty liver disease is underway, and top line results are expected in the fourth quarter of 2018.

A phase I/II trial of IMM-529 in patients with Clostridium difficile infections (CDI) is ongoing and top-line results from this study are expected in 2019.

3. Catalyst Biosciences Inc. (CBIO)

Catalyst Biosciences is focused on developing therapies for hemophilia.

CBIO was trading around $26.03 when it featured in our In the Spotlight column on February 9, 2018. It touched a 52-week high of $37.00 on February 10, 2018, reflecting a gain of 42% from the published price. The stock has given back all its gains and currently trades around $24.96.

What next?

The interim data from phase II part of the Company's phase II/III trial of Marzeptacog alfa (activated) in individuals with hemophilia A or B with inhibitors is expected to be announced in July 2018.

A phase IIb trial of CB 2679d in individuals with severe hemophilia B is expected to be initiated in the third quarter of 2018.

Interim results from Cohort 6 of phase I/II trial of CB 2679d for the treatment of severe hemophilia B are expected to be announced in the third quarter of 2018, with additional data in 4Q 2018.

4. InflaRx N.V. (IFRX)

InflaRx is a clinical-stage biopharmaceutical company focused on developing treatments for a wide variety of autoimmune and other inflammatory diseases.

IFRX was trading around $32.00 when it featured in our In the Spotlight column on February 22, 2018. It touched a 52-week high of $42.83 on May 1, 2018, reflecting a gain of 34% from the published price. The stock currently trades around $37.85.

What next?

A phase IIb study with IFX-1 in patients suffering from moderate or severe Hidradenitis Suppurativa (HS) is underway. Hidradenitis Suppurativa is a painful, chronic and debilitating inflammatory skin disease.

Initial results from the study are expected in March 2019.

5. Zymeworks Inc. (ZYME)

Zymeworks is a clinical-stage biopharmaceutical company, developing biotherapeutics, with a focus on immuno-oncology and other therapeutic areas.

ZYME was trading around $11.80 when it featured in our In the Spotlight column on March 29, 2018. It touched a 52-week high of $22.07 on May 30, 2018, reflecting a gain of 87% from the published price. The stock trades around $21.60.

What next?

Complete enrollment in phase I clinical trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers, and report additional data this year.

File an Investigational New Drug application for ZW49 in 2018. ZW49 is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload.

6. Evolus Inc. (EOLS)

Evolus, a spin-off from Alphaeon Corp., is a medical aesthetics company whose lead product candidate is DWP-450, a rival to Allergan Plc's Botox.

EOLS was trading around $9.55 when it featured in our In the Spotlight column on May 9, 2018. It touched a 52-week high of $28.47 on May 30, 2018, reflecting a gain of 198% from the published price. The stock currently trades around $24.59.

What next?

On May 16, 2018, the FDA rejected the Company's Biologics License Application for DWP-450 for the treatment of glabellar lines, also known as frown lines, in adult patients. Evolus expects to respond to the FDA within 90 days.

The Company remains committed to bringing DWP-450 to market by spring 2019.